Using recent diagnostic scans can substantially cut time to treatment for patients needing urgent palliation

Using previously taken diagnostic computed tomography (CT) scans in place of CT simulation scans to plan simple palliative radiation treatments can substantially reduce the time some people spend waiting for urgent treatment, improving the patient experience, a new study suggests.

Precision medicine navigators increase genomic testing rates for Black patients with prostate cancer

The presence of a clinical navigator to act as a liaison between people with prostate cancer and the health care system greatly increases the likelihood that patients, especially Black patients, will receive advanced testing that can help predict the severity of their disease and guide treatment, a new study suggests.

Short-course radiation as effective as standard treatment for patients who opt for breast reconstruction after mastectomy

In a first-of-its-kind study, people with breast cancer who underwent implant-based breast reconstruction immediately following a mastectomy reported that getting fewer, higher doses of radiation was just as effective as standard radiation, did not increase side effects and saved them time and money.

High cure rate, low toxicity maintained with shortened radiation treatment for intermediate risk prostate cancer, study finds

People with intermediate risk, localized prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, a new phase III randomized trial suggests.

Research Highlights for September 2023

Huntsman Cancer Institute shines the spotlight on new discoveries and cutting-edge cancer research. This month, researchers found that increasing access for Black people with prostate cancer may save lives. Also, the first patient in a new small cell lung cancer clinical trial has been enrolled, researchers are using an app to help adolescents and young adults manage cancer symptoms, and investigators are trying to reduce cognitive side-effects after chemotherapy.

UChicago Medicine breaks ground on $815M project to build state’s first freestanding cancer care and research pavilion

The University of Chicago Medicine broke ground Tuesday on its $815 million project to build the state’s first and only standalone structure dedicated to cancer care and research. The 575,000-square-foot, seven-story pavilion builds off UChicago’s decades of work and leadership in cancer research and its prestigious National Center Institute designation as a Comprehensive Cancer Center.

Radiation oncology research and clinical trial results to be featured at ASTRO’s Annual Meeting in San Diego

The American Society for Radiation Oncology (ASTRO) announced today the 10 studies to be highlighted in the 2023 ASTRO Annual Meeting press program. Researchers will discuss their findings in news briefings held October 2 and 3 at the San Diego Convention Center and via live webcast.

Study Unlocks New Insight about Breast Cancer Risk

A new study led by a researcher at New York Institute of Technology provides insight that could change how scientists and clinicians understand genetic predisposition to breast cancer, a condition that affects one in eight U.S. women in her lifetime.

July Research Highlights

Huntsman Cancer Institute investigators find a way to reduce infection after pancreatic surgery, discover the best treatment combination that’s cost effective for prostate cancer patients, and learn lung cancer patients receiving chemotherapy have more emergency department visits. They also found a genetic mutation that makes anemia more likely after chemotherapy, and a non-invasive way to remove brain tumors.

Penn State Health Children’s Hospital, Penn State College of Medicine bring international research consortium to Hershey to strengthen their fight against childhood cancer

Penn State Health and Penn State College of Medicine are strengthening their commitment to curing childhood cancer by bringing Dr. Giselle Saulnier Sholler, an internationally known physician-scientist, and her research consortium to Hershey.

Cancer Research Institute Awards Over $28 Million in Grants to Fuel Immunotherapy Innovations

The Cancer Research Institute awarded $28.7 million in research grants and fellowships in the 2023 fiscal year ending June 30, 2023. In total, CRI distributed 73 awards that will advance cancer immunology research at 41 institutions in 10 countries. CRI grants were awarded to support projects involving a variety of immune-based approaches as well as the development of novel technologies that may help pave the way for the next generation of immunotherapies.

Antibody Treatment Prevents Graft Versus Host Disease, a Major Bone Marrow Transplant Complication, in Advanced Preclinical Tests

An experimental antibody treatment largely prevented a bone marrow transplant complication called graft versus host disease (GVHD) in the intestines, without causing broad immune suppression, in a preclinical study led by researchers from Penn Medicine and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and published today in Science Translational Medicine.

KU Cancer Center receives historic $100 million gift from Sunderland Foundation to support new cancer research and care facility

The University of Kansas Cancer Center has received a $100 million lead gift to build a new, state-of-the-art destination cancer center. This gift is both the largest gift ever given by the Sunderland Foundation and the largest ever received by the University of Kansas and The University of Kansas Health System.

Markey Cancer Center study reveals persistent cancer disparities in Appalachian Kentucky

A recent University of Kentucky Markey Cancer Center study published in The Journal of Rural Health sheds light on Appalachian Kentucky’s alarming cancer burden, revealing striking disparities compared to non-Appalachian Kentucky and the rest of the country.Kentucky ranks first in the nation for cancer incidence and mortality rates, and Appalachian Kentucky bears the state’s greatest cancer burden, driven by disparities in health behaviors, such as smoking, and lower rates of cancer screening.

Fine-tuning 3D lab-grown mini tumors to help predict how patients respond to cancer therapies

Scientists from the UCLA Jonsson Comprehensive Cancer Center have developed a new method to bioprint miniature tumor organoids that are designed to mimic the function and architecture of real tumors. The improved process allows researchers to use an advanced imaging method to study and analyze individual organoids in great detail, which can help researchers identify personalized treatments for people with rare or hard-to-treat cancers.

ASCO: HER2-targeted antibody drug conjugate shows strong anti-tumor activity and durable responses across multiple tumor types

In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types. These data from an interim analysis of the Phase II DESTINY-PanTumor02 study, led by The University of Texas MD Anderson Cancer Center, were presented today at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

ASCO: Targeted therapy for early breast cancer, progress treating recurrent glioma, PSMA PET scan advances and more

Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest research and clinical trial results on combination therapies for breast cancer, a potential new treatment for patients with recurrent glioma, and advances in PSMA PET guided radiotherapy for patients with prostate cancer, among other topics, at the American Society of Clinical Oncology’s annual meeting.

American Society for Radiation Oncology (ASTRO) to host Annual Meeting in San Diego, October 1-4

Registration opens today for the American Society for Radiation Oncology’s (ASTRO) 65th Annual Meeting, which will be held at the San Diego Convention Center, October 1-4, 2023. Media registration is available at, and general registration is available at

New Computational Tool Identifies Novel Targets for Cancer Immunotherapy

Researchers at Children’s Hospital of Philadelphia (CHOP) and the University of California, Los Angeles (UCLA) have developed a computational platform capable of discovering tumor antigens derived from alternative RNA splicing, expanding the pool of cancer immunotherapy targets. The tool, called “Isoform peptides from RNA splicing for Immunotherapy target Screening” (IRIS), was described in a paper published today in the Proceedings of the National Academy of Sciences.

Computational biology superstar Sanju Sinha joins Sanford Burnham Prebys

Sanju Sinha, Ph.D., has joined Sanford Burnham Prebys as an assistant professor in the Cancer Molecular Therapeutics Program to continue his research on cancer development and drug discovery. He comes to Sanford Burnham Prebys from the Cancer Data Science Lab at the National Cancer Institute (NCI), where he trained to leverage the power of artificial intelligence to discover new drugs to prevent cancer.

Markey Cancer Center study identifies new treatment target for metastatic cancer

A new University of Kentucky Markey Cancer Center study reveals more about changes that happen to cancer cells when they metastasize and identifies a promising target for the treatment of metastatic breast cancer.Metastasis is when cancer cells spread from the primary tumor to surrounding tissues and distant organs in the body and is the primary cause for breast cancer mortality.